Hydrolysis of the tumor-associated antigen epitope gp100280-288 by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells

Clinical Immunology

Volumn 111, Issue 3, 2004, Pages 252-261

  Cavazza, Antonella ^a   Adamina, Michel ^b   Ausiello, Clara M ^c   Giardina, Bruno ^d   Marini, Mario ^a   Palazzo, Raffaella ^c   Roda, L Giorgio ^a   Spagnoli, Giulio C ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF BASEL   (Switzerland)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Dendritic cells; Human; Maturation; Peptides; Tumor immunity; Vaccination

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; TUMOR ANTIGEN;

ARTICLE; CELL MATURATION; CHROMATOGRAPHY; CONTROLLED STUDY; DEGRADATION KINETICS; DENDRITIC CELL; HUMAN; HUMAN CELL; HYDROLYSIS KINETICS; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; TUMOR IMMUNITY;

AMINO ACIDS; AMINOPEPTIDASES; ANTIGENS, NEOPLASM; CARBOXYPEPTIDASES; CELLS, CULTURED; CHROMATOGRAPHY; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; EPITOPES; HLA-A2 ANTIGEN; HUMANS; HYDROLYSIS; MEMBRANE GLYCOPROTEINS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 2942534491     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.02.006     Document Type: Article

References (37)

1. Harty J.T., Bevan M.J. Responses of CD8(+) T cells to intracellular bacteria. Curr. Opin. Immunol. 11:1999;89-93
2. Gapin L., Bravo de Alba Y., Casrouge A., Cabaniols J.P., Kourilsky P., Kanellopuolos J. Antigen presentation by dendritic cells focuses T cell response against immunodominant peptides: studies in the hen egg white lysozyme (HEL) model. J. Immunol. 160:1998;1555-1564
3. Valmori D., Gileadi U., Servis C., Dunbar P.R., Cerottini J.C., Romero P., Cerundolo V., Levy F. Modulation of proteosomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189:1999;895-906
4. Boon T., Cerottini J.C., Vandeneynde B., Vanderbruggen P., Vanpel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:1994;337-365
5. Urban J.L., Schreiber H. Tumor antigens. Annu. Rev. Immunol. 10:1992;617-644
6. Houghton A.N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1994;1-4
7. Oertli D., Marti W.R., Zajac P., Noppen C., Kocher T., Padovan E., Adamina M., Schumacher R., Harder F., Heberer M., Spagnoli G.C. Rapid induction of cytotoxic T-lymphocytes against melanoma associated antigens by a recombinant vaccinia virus vector expressing immunodominant epitopes and costimulatory molecules in vivo. Hum. Gene Ther. 13:2002;569-575
8. Bellone M., Cantarella D., Castiglioni P., Crosti M.C., Ronchetti A., Moro M., Garancini M.P., Casorati G., Dellabona P. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165:2000;2651-2656
9. Manickan E., Karem K.L., Rouse B.T. DNA vaccines - A modern gimmick or a boon to vaccinology? Crit. Rev. Immunol. 17:1997;139-154
10. Vitiello A., Potter T.A., Sherman L.A. The role of beta2-microglobulin in peptide binding by class I molecules. Science. 250:1990;1423-1426
11. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/monocyte colony-stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor alpha. J. Exp. Med. 179:1994;1109-1118
12. Romani N., Schuler G. The immunological properties of epidermal Langerhans cells as part of the dendritic cell system. Springer Semin. Immunopathol. 13:1992;265-279
13. Padovan E., Spagnoli G.C., Ferrantini M., Heberer M. IFN-α2a induces IP-10/CXCL10 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector cells. J. Leukocyte Biol. 71:2002;669-676
14. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332
15. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Driesh P., Brocker E.B., Steinman R., Enk A., Kampgen E., Schuler G. Vaccination with mage-3A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1999;1669-1678
16. Boderke P., Merkle H.P., Cullander C., Ponec M., Bodde H. Localization of aminopeptidase activity in freshly excised human skin: direct visualization by confocal laser scanning microscopy. J. Invest. Dermatol. 108:1997;83-86
17. Lee V.H.L. Enzymatic barriers to peptide and protein absorption. CRC Crit. Rev. Ther. Drug Carrier Syst. 5:1988;69-97
18. Caughey G.H., Leidig F., Viro N.F., Nadel J.A. Substance P and vasoactive intestinal peptides degradation by mast cell tryptase and chymase. J. Pharmacol. Exp. Ther. 244:1988;133-137
19. Bongiorno L., Marini M., Urbani A., Ausiello A.C.M., Roda L.G. Effect of stimulation on soluble proteolytic enzymes released by peripheral blood mononucleate cells. Int. J. Immunopharmacol. 15:1993;621-629
20. Amoscato A.A., Prenovitz D.A., Lotze M.T. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. 161:1998;4023-4032
21. 280-288 by the monocyte-like U937 cell line. Peptides. 24:2003;371-378
22. Bakker A.B.H., van der Burg S.H., Huijbens R.J., Drijfhout J.W., Melief C.J., Adema G.J., Frigdor C.G. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer. 70:1997;302-309
23. 27-35 peptide: implications for peptide vaccines. Int. J. Cancer. 83:1999;326-334
24. Blanchet J.S., Valmori D., Dufau I., Ayyoub M., Nguyen C., Guillaume P., Monsarrat B., Cerottini J.C., Romero P., Gairin J.E. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J. Immunol. 15:2001;5852-5861
25. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., Engelhard V.H., Hunt D.F., Slingluff C.L. Identification of a peptide recognized by five melanoma-specific human cytotoxic cell lines. Science. 264:1994;716-719
26. Cochrane D.E., Carraway R.E., Boucher W., Feldberg R.S. Rapid degradation of neurotensin by stimulated rat mast cells. Peptides. 12:1991;1187-1194
27. Werfel T., Sonntag G., Weber M.H., Gotze O. Rapid increases in the membrane of neutral endopeptidase (Cd10), aminopeptidase N (CD13), tyrosine phosphatese (CD45) and Fc gamma-RIII (CD16) upon stimulation of human peripheral leucocytes with human C5a. J. Immunol. 147:1991;3909-3914
28. Ausiello C.M., Fedele G., Urbani F., Lande R., Di Carlo B., Cassone A. Native and genetically-inactivated per tussis toxins induce human dendritic cell maturation and synergize with LPS in promoting T helper type 1 responses. J. Infect. Dis. 186:2002;351-360
29. Remmel E., Terracciano L., Noppen C., Zajac P., Heberer M., Spagnoli G.C., Padovan E. Modulation of dendritic cell phenotype and mobility by tumor cells in vitro. Hum. Immunol. 62:2001;39-49
30. Momburg F., Ortiz-Navarrete V., Neefjes J., Goulmy E., van der Wal Y., Spits H., Powis S.J., Butcher G.W., Howard J.C., Walden P., Hämmerling G.J. Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature. 360:1992;174-177
31. Noppen C., Levy F., Burri L., Zajac P., Remmel E., Schaefer C., Luscher U., Heberer M., Spagnoli G.C. Naturally processed and concealed HLA-A21-restricted epitopes from tumor-associated antigen tirosinase-related protein-2. Int. J. Cancer. 87:2000;241-246
32. Babbitt B.P., Allen P.M., Matsueda G., Haber E., Unuanue E.R. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature. 317:1985;359-361
33. Widmann C., Maryanski J.L., Romero P., Corradin G. Differential stability of antigenic MHC class-I restricted synthetic peptides. J. Immunol. 147:1991;3745-3751
34. Powell M.F., Grey H., Gaeta F., Sette A., Colon S. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J. Pharmacol. Sci. 81:1992;731-735
35. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell. 106:2001;263-266
36. Matzinger P. The danger model: a renewed sense of self. Science. 296:2002;301-305
37. Roscetti G., Bongiorno L., Urbani A., Marini M., Roda L.G. Hydrolysis and binding of leucine enkephalin to lymphomic and erythroleukaemic cell lines. Int. J. Immunopharmacol. 12:1990;391-396